COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER

COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Marinello, Patricia, Perini, Rodolfo Fleury, Healy, Jane Anne, Jha, Sujata Shrawankuma, Willemann Rogerio, Jaqueline
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.